NasdaqGS:ADPTLife Sciences
Adaptive Biotechnologies (ADPT): Valuation Check After New Pfizer T-Cell Discovery and AI Drug Collaboration Deals
Adaptive Biotechnologies (ADPT) just signed two non exclusive deals with Pfizer that put its T cell receptor discovery platform and massive antigen mapping dataset at the center of Pfizer’s rheumatoid arthritis and AI driven drug discovery work.
See our latest analysis for Adaptive Biotechnologies.
The Pfizer collaborations come on top of an already sharp re rating, with a roughly 181 percent year to date share price return and a 175 percent one year total shareholder return suggesting...